Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is listed among the best US stocks under $10 to invest in. Analyst Catherine Novack raised the price target to $9.00 from $6.00, reflecting a potential upside of about 66.98% following FDA approval of its NDA resubmission for Reproxalap in treating dry eye disease.

The U.S. FDA accepted Aldeyra Therapeutics, Inc.’s (NASDAQ:ALDX) NDA resubmission for Reproxalap, setting a target action date of December 16, 2025. If approved, AbbVie may pay $100 million upfront and share US profits, reducing commercialization risks. The company’s platform includes follow-on assets like ADX-629 and ADX-2191.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a Massachusetts-based biotech company focused on immune-mediated and metabolic diseases since 2004. Despite its investment potential, other AI stocks may offer better upside and lower risks. For an undervalued AI stock benefiting from onshoring trends, refer to the free report on the best short-term AI stock.

Read more at Yahoo Finance: JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9